Laronib (Larotrectinib) 25mg/100mg×30 Capsules | Everest Bangladesh NTRK Fusion | GLT

Generic Information: Laronib (Larotrectinib) — Everest Pharmaceuticals, Bangladesh

Laronib is the larotrectinib capsule of Everest Pharmaceuticals Ltd., the Dhaka-headquartered manufacturer that launched it in July 2019 as the world's first generic of this tissue-agnostic TRK inhibitor. The range is deliberately complete for titration: two strengths, 25 mg and 100 mg, each in a 30-capsule bottle, so prescribers can step a patient up from the starting dose or down for tolerability using the same brand. That two-strength design mirrors the originator's capsule options and matters for anyone managing the 100 mg twice-daily standard against the 75 mg and 50 mg reduction steps.

What Is Laronib (Larotrectinib) Used For?

Laronib treats adult and pediatric patients with solid tumors that carry a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, where disease is metastatic or surgery would risk severe morbidity, and where there is no satisfactory alternative or the cancer has progressed after treatment. Because the drug is selected by fusion status rather than tumor location, one brand serves salivary gland cancer, soft-tissue sarcoma, infantile fibrosarcoma, thyroid cancer, lung cancer and other NTRK fusion-positive solid tumors.

How Does Laronib (Larotrectinib) Work?

The active ingredient is a highly selective, ATP-competitive inhibitor of the tropomyosin receptor kinase (TRK) family — TRKA, TRKB and TRKC, the proteins encoded by NTRK1, NTRK2 and NTRK3. An NTRK fusion creates an always-active TRK fusion protein that drives tumor growth; blocking all three TRK kinases cuts that signal and shrinks tumors across tissues. The capsule is the same sulfate salt formulation as the originator, taken orally twice daily.

Indications of Laronib (Bangladesh Label)

The Bangladesh label mirrors the originator's tissue-agnostic indication: NTRK fusion-positive solid tumors without acquired resistance, locally advanced or metastatic or high-risk-for-surgery, and no satisfactory alternative or progression after prior therapy. As a generic of a drug approved under FDA accelerated approval, Laronib inherits the same patient-selection rule — a validated test must confirm the fusion before treatment, because the drug has no meaningful activity against fusion-negative tumors.

Dosage and Administration

The standard dose is 100 mg orally twice daily for adults and children with body surface area of at least 1.0 m², with or without food, until progression or unacceptable toxicity; children below 1.0 m² receive 100 mg/m² twice daily. The 25 mg capsule exists for dose reductions — 75 mg twice daily is given as a 25 mg plus a 50 mg, and the 50 mg step uses two 25 mg capsules, while the 100 mg once-daily step uses the full-strength capsule once. Capsules are swallowed whole, never chewed or crushed, and a missed dose is skipped if it is within six hours of the next one.

Side Effects of Laronib

Expect the class profile: fatigue, nausea, dizziness, vomiting, cough, constipation, diarrhea and raised AST and ALT in at least 20% of patients. Neurotoxicity — dizziness, cognitive changes, mood and sleep disturbance — calls for caution with driving and machinery, and hepatotoxicity is managed with liver-function monitoring every two weeks early on, then monthly. Skeletal fractures warrant prompt evaluation, and because the drug can harm a fetus, effective contraception is required during and for one week after treatment.

Storage Instructions

Store the 30-capsule bottles at room temperature in a closed container protected from moisture, out of children's reach. Everest's Bangladesh stock is export-oriented and ships with a batch number and certificate of analysis, so a buyer can verify the generic's provenance against the manufacturer's records — a meaningful safeguard for a medicine that crosses international borders.

Why Choose Laronib from GLT?

Laronib is the value option for buyers who want the world's first generic with both 25 mg and 100 mg strengths for flexible dosing. GLT quotes it alongside the originator Vitrakvi and the other generics (Tractoni, LuciLaro, Larotreni, Larodx) so the full NTRK price ladder is visible before a decision, and sealed stock with pre-shipment photographs and export documentation comes standard. A real person answers on WhatsApp +86 15234153837 or at [email protected] for every step.

How to Order Laronib (Larotrectinib)

Message GLT on WhatsApp +86 15234153837 or write to [email protected] with the strength, bottle quantity and destination. A formal quotation with courier and payment options returns within a working day, and recurring monthly supply can be scheduled for patients on continuous therapy. Confirmed orders ship sealed with complete export paperwork.

FAQ

Why two strengths, 25 mg and 100 mg? The 100 mg capsule is the standard twice-daily dose; the 25 mg capsule supports the 75 mg and 50 mg dose-reduction steps used when tolerability requires it.

Is Laronib the first generic? Yes — Everest launched it in July 2019 as the first generic of larotrectinib worldwide.

Does it need a gene test? Yes, an NTRK fusion must be confirmed by a validated test before treatment.

Is it the same as Vitrakvi? Same active ingredient and dose; Laronib is the Bangladesh generic at a lower price point.

Can children take it? Yes, with body-surface-area-based dosing as in the originator label.